Trial Profile
A cluster randomized, single-centre, controlled, parallel,12-month prospective study and additional 12-month follow-up in Africa of malaria incidence in a community setting following systematic treatment of P. Falciparum asymptomatic carriers with artemether-lumefantrine (Coartem/Coartem Dispersible)
Status:
Not stated
Phase of Trial:
Phase IV
Latest Information Update: 07 Apr 2016
Price :
$35
*
At a glance
- Drugs Artemether/lumefantrine (Primary)
- Indications Malaria
- Focus Therapeutic Use
- Sponsors Novartis
- 07 Apr 2016 New trial record